MiMedx says FTC issued Second Request on Sanara merger review
MiMedx and Sanara MedTech each received a Second Request from the Federal Trade Commission on October 15, 2026, as part of the FTC's review of their proposed merger. The request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, which could delay closing; the filing gives no expected timing.
Key points
- FTC issued Second Requests to MiMedx and Sanara on October 15, 2026.
- Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended voluntarily or ended earlier by the FTC.
- Completion still depends on HSR waiting period expiration and other closing conditions; MiMedx says it continues to work constructively with the FTC.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.